ACC 2020 The ODYSSEY HoFH trial demonstrated that treatment with alirocumab reduced LDL-c in HoFH patients compared to placebo, and alirocumab was found to be well tolerated and safe.
This post hoc analysis of the DM-DYSLIPIDEMIA study shows that, in a high risk subgroup of T2DM patients with mixed dyslipidemia, alirocumab treatment is more effective in reducing ApoB and non-HDL-c as compared to usual treatment.
Jorge Plutzky talks about an approach implemented in the Brigham and Women's Hospital, that uses an algorithm to select type of medication per individual to achieve target LDL-c levels.
At the end of the FOURIER trial, participants filled out a questionnaire on their memory, cognitive and executive function. No differences on cognition were noted between treatment groups.
Prof. Ray explains how he decides on the amount of LDL-c lowering that is needed in a given patient, and why he chooses this approach.
The open-label TAUSSIG study evaluated treatment with evolocumab during a median follow-up of 4.1 years and found a similar safety profile and good LDL-c lowering in HoFH and HeFH patients
A subanalysis of FOURIER found that patients with recent MI (<12 months) had greater relative and absolute treatment benefit of evolocumab than those with remote MI.
The new ESC/EAS Dyslipidaemia Guidelines focus on high-risk patients, and prof. Laufs shares evidence for the treatment recommendations. Test your knowledge
Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.
Prof. Lüscher paints a picture of how atherosclerosis has been a fact of human life throughout time, and the evolution of insights on how to lower LDL-c and its associated CV risk.
This video series addresses the role of PCSK9 inhibiting approaches in treating hypercholesterolemia and in preventing CV events in patients at high and very high CV risk. Member registration (free) is needed to enroll in this course.
AHA 2019 The ORION-10 trial met all its primary and secundary efficacy endpoints, with a good safety profile, up to 17 months.